In a recent study posted to the medRxiv* preprint server, researchers in the United States assessed the efficiency of protection mediated by antibodies against symptomatic coronavirus disease 2019 (COVID-19) at low serum-neutralizing titers.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero